A collection of genes utilized by the RNA interference (RNAi) pathway; the RNAi pathway is a biological process in which RNA molecules inhibit gene expression or translation by neutralizing targeted mRNA molecules. Ideal for genetic screening.
Targets 1,817 genes with up to 4 gRNA per gene target for a total of 7,268 gRNAs. Libraries are delivered as 50μL of glycerol stock per gRNA and are also available as ready to use packaged lentivirus
Targets 510 genes commonly involved in the development of cancer with up to 4 gRNA per gene target for a total of 2,040 gRNAs. Libraries are delivered as 50μL of glycerol stock per gRNA and are also available as ready to use packaged lentivirus.
Targets 396 genes with up to 4 gRNA per gene target for a total of 1,548 gRNAs. Libraries are delivered as 50μL of glycerol stock per gRNA and are also available as ready to use packaged lentivirus
Targets 822 genes with up to 4 gRNA per gene target for a total of 3,288 gRNAs. Libraries are delivered as 50μL of glycerol stock per gRNA and are also available as ready to use packaged lentivirus.
The Silencer™ Select Human Epigenetics siRNA Library contains 1563 Ambion™ Silencer Select highly potent, chemically-modified siRNAs targeting 521 epigenetic enzymes, including those mediating epigenetic signaling through the acetylation and methylation of histones.
The award-winning Invitrogen™ LentiArray™ Human Whole Genome Library targets 18,453 genes with up to 4 gRNA per gene target (pooled in a single well) for a total of 73,812 gRNAs.
The Silencer Select Human Drug Targets siRNA Library contains 23,778 Invitrogen™ Silencer Select highly potent and chemically-modified siRNAs targeting 7,926 genes for performing RNAi screens against known human drug target genes.
The Silencer Human Drug Targets siRNA Library contains 23,745 Invitrogen™ Silencer siRNAs targeting 7,915 genes for performing RNAi screens against known human drug target genes.
Mutations that cause a loss or reduction in gene function can result in the progression to cancer, usually in combination with other genetic changes. Tumor suppressor genes, or anti-oncogenes, can protect cells on the path to becoming cancerous.
DNA surveillance proteins monitor DNA integrity, and they can activate cell cycle checkpoints and DNA repair pathways in response to DNA damage. This can prevent potentially deleterious mutations.